pharmaphorum| News & views on pharma and biotech’s evolving future

News

Lilly's triple agonist retatrutide passes diabetes test

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.

News

Black and white letters spelling out 'Mental Health Matters' on a grey background

Precision psychiatry push starts in Europe

As geopolitical tensions ratchet up around the world, an initiative has been launched to drive improvements in diagnostic accuracy and precision care.

R&D

Redesigning obesity trials for a chronic disease era

News

Generic semaglutide in India, and other weight-loss news

Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.

News

Alfasigma claims early FDA nod for ex-GSK liver drug

Alfasigma has claimed the first approval, in the US, for linerixibat, a drug for liver disease PBC licensed from GSK for $690m a few days ago.

Featured Content

Patients

Bringing awareness to Brain Tumour Month, personally

This Brain Tumour Awareness Month, Inventus' Jim Michel reveals how living with a benign brain tumour has influenced his life.

R&D

Redesigning obesity trials for a chronic disease era

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

Patients

Interview at JPM26 with Alexander Schneider

New hope for ovarian cancer, with Alexander Schneider

Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.

Digital

Sponsored

Expert Directed Applied Intelligence: Redefining AI in Life ...

In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.

Newsletters and Deep Dive
digital magazine

Latest News

News

Lilly's triple agonist retatrutide passes diabetes test

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.

News

Precision psychiatry push starts in Europe

As geopolitical tensions ratchet up around the world, an initiative has been launched to drive improvements in diagnostic accuracy and precision care.

News

Generic semaglutide in India, and other weight-loss news

Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.

News

Alfasigma claims early FDA nod for ex-GSK liver drug

Alfasigma has claimed the first approval, in the US, for linerixibat, a drug for liver disease PBC licensed from GSK for $690m a few days ago.

Views & Analysis

Patients

Bringing awareness to Brain Tumour Month, personally

This Brain Tumour Awareness Month, Inventus' Jim Michel reveals how living with a benign brain tumour has influenced his life.

Digital

Why pharma’s digital health tools miss the mark

Explore the cultural, operational, and value-definition shifts required for digital health to deliver durable impact.

Patients

The hidden access gap in Europe’s lung cancer hospital data

New hospital-level analysis shows a provider landscape that is more concentrated, regionally uneven & strategically complex than commercially assumed.

R&D

pharmaphorum podcast Episode 250, Rob DiCicco, Transcelerate

Making AI work where it matters, with Rob DiCicco

Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

GLP-1s: Five years that changed metabolic medicine

R&D

Redesigning obesity trials for a chronic disease era

R&D

The trust gap: GLP-1s and the new information economy of obe...

White Papers & Webinar

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Digital

Sponsored

Expert Directed Applied Intelligence: Redefining AI in Life ...

In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.

Sales & Marketing

Lumanity white paper - person at top of mountain range

Sponsored

The strategic imperative of Integrated Evidence Generation P...

Integrated Evidence Generation Planning (IEGP) is recognised as a strategic necessity for biopharmaceutical organisations.

Digital

White paper from Veeva on Clinical Data Industry Research

Sponsored

Data managers and CRAs warn of rising data quality risks due...

A new industry report uncovers the scope of a long-ignored problem in clinical trial operations.

Podcasts & Video

R&D

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

R&D

pharmaphorum podcast Episode 248, Andrew Mackinnon, Medable

AI in clinical development & ‘white space’, with Andrew Mack...

Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Market Access

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...

Unpack the impact of Most-Favoured Nations in GLOBE and GUARD pricing models, and TrumpRx, with Alice Valder Curran's clear policy overview.

The Pharmaceutical Marketing Society (PM Society) today announces the launch of Pharmony

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content